« ICH M7 Guidance on Assessment of Impurities in Pharmaceutical Products | Main | eCheminfo workshop will apply OpenTox to generating evidence on potential toxic liabilities in anti-malarial drug design »

May 25, 2014

Comments

The comments to this entry are closed.

Communities of Practice